HOME Top Market Reports Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017)

Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 – 2017)

By: marketsandmarkets.com
Publishing Date: October 2012
Report Code: PH 1301

Discount on Reports  

  Speak to Analyst Enquiry Before Buying
 
purchase report
download pdf  request for customisation


Biosimulation refers to computer aided simulation of biological processes and systems, an integral part of systems biology used in drug discovery and development. This report will analyze the potential of biosimulation in drug discovery and development. Biosimulation is used across the drug discovery and development program (such as target identification, target validation, lead discovery, lead optimization, preclinical and clinical test).

The global biosimulation market was valued at $432 million in 2011 and is expected to reach $1.2 billion by 2017, at a CAGR of 18.5%. Modelling and simulation in preclinical and clinical stages contributed maximum share (60%) to the global biosimulation market in 2011.

The major driving factor for this market is the cost and time spent on drug discovery and development programs and failure of drug candidates in the late development stages. Pharmaceutical companies around the globe spent around $68 billion in 2011 in drug discovery and development programs, many of the drug discovery and development programs fail in the late stages of the clinical trials wasting all the years of efforts and money. There is a need for predictive technology which would outlay the outcome of a drug candidate in the discovery stages; biosimulation is one such technology which can bring down the cost on drug discovery and development programmes by focusing on promising lead drug candidates and experiments.

North America is the biggest market for biosimulation followed by Europe. North America which is the largest drug market in the world contributes one third for the global biosimulation market. Europe is the fastest growing market for biosimulation and the growth is attributed to the efforts of regulatory bodies in promoting new technologies in drug discovery and development. Asian market is still considered to be in development stages because of non availability of skilled workforce and infrastructure in place.

Major players in the market includes Accelrys, Schrodinger, Certara, Simulation plus, Rhenovia, ACD/Labs, CCG, LeadScope, Entelos, Genedata, Optimata among others.

TABLE OF CONTENTS

1 INTRODUCTION
  1.1 KEY TAKE AWAYS
  1.2 REPORT DESCRIPTION
  1.3 MARKETS COVERED
  1.4 STAKEHOLDERS
  1.5 RESEARCH METHODOLOGY
      1.5.1 MARKET SIZE
      1.5.2 MARKET SHARE
      1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
      1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
  3.1 INTRODUCTION
  3.2 MARKET SEGMENTATION
  3.3 MARKET DYNAMICS
      3.3.1 DRIVERS
            3.3.1.1 Need for new tools in drug discovery process
            3.3.1.2 Increased spending on healthcare
            3.3.1.3 Cost attributed to the traditional drug discovery process
            3.3.1.4 Failure of drug candidates in the late development stages
            3.3.1.5 Improved computational power
            3.3.1.6 Improved modelling & simulation tools
      3.3.2 RESTRAINTS
            3.3.2.1 Unproven predictive methodology
            3.3.2.2 Risk of Potential safe drug failing in biosimulation
            3.3.2.3 Lack of standardization
            3.3.2.4 Limited knowledge of biological systems & process
      3.3.3 CHALLENGES
            3.3.3.1 Increasing accuracy in prediction
            3.3.3.2 Increasing collaboration/partnership among vendors & pharmaceutical companies
            3.3.3.3 Integration of other technologies for better predictive models
      3.3.4 TRENDS
            3.3.4.1 Drug repositioning
            3.3.4.2 In Patient medication
      3.3.5 SWOT ANALYSIS
            3.3.5.1 Strengths
            3.3.5.2 Weakness
            3.3.5.3 Opportunities
            3.3.5.4 Threats

4 GLOBAL BIOSIMULATION MARKET, BY APPLICATION
  4.1 SEGMENTATION BASED ON APPLICATIONS
  4.2 APPLICATION IN DRUG DISCOVERY
      4.2.1 TARGET IDENTIFICATION
            4.2.1.1 Protein structure prediction
      4.2.2 TARGET VALIDATION
            4.2.2.1 Molecular modeling (Protein modelling software)
      4.2.3 LEAD IDENTIFICATION/DISCOVERY
            4.2.3.1 De novo Design
      4.2.4 LEAD OPTIMIZATION
            4.2.4.1 QSAR (Quantitative structure–activity relationship) Models
  4.3 APPLICATION IN DRUG DEVELOPMENT
      4.3.1 PRE-CLINICAL TESTING
            4.3.1.1 ADME/Tox prediction
            4.3.1.2 Pharmacokinetic/Pharmacodynamic (PK/PD) models (pharmacokinetic/Pharmacodymanic simulation)
      4.3.2 CLINICAL TRIALS
            4.3.2.1 Phase I clinical trial
            4.3.2.2 Phase II clinical trial
            4.3.2.3 Phase III clinical trial
      4.3.3 IN PATIENT VALIDATION (HUMAN BODY SIMULATION SOFTWARE)

5 CURRENT TRENDS &DEVELOPMENTS
  5.1 MODELING AND SIMULATIONS IN PAEDIATRICS DRUG DEVELOPMENT
  5.2 MODELLING & SIMULATIONS IN NEGLECTED DISEASES DRUG DEVELOPMENT (MODELS OF HUMAN DISEASES)
      5.2.1 DRUG REPOSITIONING
      5.2.2 GRID ENABLED DRUG DISCOVERY MODEL

6 GEOGRAPHIC ANALYSIS
  6.1 INTRODUCTION
  6.2 NORTH AMERICA
  6.3 EUROPE
  6.4 ASIA
  6.5 REST OF THE WORLD
  6.6 TRENDS IN ASIA

7 COMPETITIVE LANDSCAPE
  7.1 INTRODUCTION
  7.2 PORTER’S FIVE FORCE ANALYSIS
  7.3 MERGERS & ACQUISITIONS
  7.4 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS & JOINT VENTURES
  7.5 NEW PRODUCT LAUNCHES

8 COMPANY PROFILE
  8.1 ACCELYRS, INC.
      8.1.1 OVERVIEW
      8.1.2 FINANCIALS
      8.1.3 PRODUCTS & SERVICES
      8.1.4 STRATEGY
      8.1.5 DEVELOPMENTS
  8.2 ADVANCED CHEMISTRY DEVELOPMENT (ACD/LABS)
      8.2.1 OVERVIEW
      8.2.2 PRODUCTS & SERVICES
      8.2.3 STRATEGY
      8.2.4 DEVELOPMENTS
  8.3 ARCHIMEDES, INC.
      8.3.1 OVERVIEW
      8.3.2 PRODUCTS & SERVICES
      8.3.3 DEVELOPMENTS
  8.4 CERTARA
      8.4.1 OVERVIEW
      8.4.2 PRODUCTS & SERVICES
      8.4.3 STRATEGY
      8.4.4 DEVELOPMENTS
  8.5 CHEMICAL COMPUTING GROUP
      8.5.1 OVERVIEW
      8.5.2 PRODUCTS & SERVICES
      8.5.3 STRATEGY
      8.5.4 DEVELOPMENTS
  8.6 COMPUGEN
      8.6.1 OVERVIEW
      8.6.2 FINANCIALS
      8.6.3 PRODUCTS & SERVICES
      8.6.4 DEVELOPMENTS
  8.7 ENTELOS, INC.
      8.7.1 OVERVIEW
      8.7.2 PRODUCTS & SERVICES
      8.7.3 DEVELOPMENTS
  8.8 GENEDATA AG
      8.8.1 OVERVIEW
      8.8.2 PRODUCTS & SERVICES
      8.8.3 STRATEGY
      8.8.4 DEVELOPMENTS
  8.9 IN SILICO BIOSCIENCES, INC.
      8.9.1 OVERVIEW
      8.9.2 PRODUCTS & SERVICES
  8.10 INHIBOX, LTD
       8.10.1 OVERVIEW
       8.10.2 PRODUCTS & SERVICES
       8.10.3 DEVELOPMENTS
  8.11 INSILICO BIOTECHNOLOGY AG
       8.11.1 OVERVIEW
       8.11.2 PRODUCTS & SERVICES
       8.11.3 DEVELOPMENTS
  8.12 LEADINVENT
       8.12.1 OVERVIEW
       8.12.2 PRODUCTS & SERVICES
  8.13 LEADSCOPE, INC.
       8.13.1 OVERVIEW
       8.13.2 PRODUCTS & SERVICES
       8.13.3 STRATEGY
  8.14 MOLECULAR KNOWLEDGE SYSTEMS, INC.
       8.14.1 OVERVIEW
       8.14.2 PRODUCTS & SERVICES
       8.14.3 DEVELOPMENTS
  8.15 NIMBUS DISCOVERY LLC
       8.15.1 OVERVIEW
       8.15.2 PRODUCTS & SERVICES
       8.15.3 DEVELOPMENTS
  8.16 OPEN EYE SCIENTIFIC SOFTWARE, INC.
       8.16.1 OVERVIEW
       8.16.2 PRODUCTS & SERVICES
       8.16.3 DEVELOPMENTS
  8.17 PHYSIOMICS PLC
       8.17.1 OVERVIEW
       8.17.2 FINANCIALS
       8.17.3 PRODUCTS & SERVICES
       8.17.4 STRATEGY
       8.17.5 DEVELOPMENT
  8.18 RHENOVIA PHARMA S.A.S
       8.18.1 OVERVIEW
       8.18.2 PRODUCTS & SERVICES
       8.18.3 STRATEGY
       8.18.4 DEVELOPMENTS
  8.19 SCHRODINGER
       8.19.1 OVERVIEW
       8.19.2 FINANCIALS
       8.19.3 PRODUCTS & SERVICES
       8.19.4 STRATEGY
       8.19.5 DEVELOPMENTS
  8.20 SIMULATIONS PLUS, INC.
       8.20.1 OVERVIEW
       8.20.2 FINANCIALS
       8.20.3 PRODUCTS & SERVICES
       8.20.4 STRATEGY
       8.20.5 DEVELOPMENTS
  8.21 SYNERGIX LTD
       8.21.1 OVERVIEW
       8.21.2 PRODUCTS & SERVICES
       8.21.3 DEVELOPMENTS
 

LIST OF TABLES

TABLE 1 COST & TIME INVOLVED IN DRUG DISCOVERY PROCESS
TABLE 2 BIOSIMULATION MARKET REVENUE, BY GEOGRAPHY,2012 – 2017 ($MILLION)
TABLE 3 INSILICO TARGET IDENTIFICATION MARKET REVENUE, BY GEOGRAPHY,2012 – 2017 ($MILLION)
TABLE 4 INSILICO TARGET VALIDATION MARKET REVENUE, BY GEOGRAPHY,2012 – 2017 ($MILLION)
TABLE 5 INSILICO LEAD DISCOVERY MARKET REVENUE, BY GEOGRAPHY,2012 – 2017 ($MILLION)
TABLE 6 INSILICO LEAD OPTIMIZATION MARKET REVENUE, BY GEOGRAPHY,  2012 – 2017 ($MILLION)
TABLE 7 INSILICO ADME/TOX PREDICTION MARKET REVENUE, BY GEOGRAPHY,2012 – 2017 ($MILLION)
TABLE 8 INSILICO PK/PD MODEL MARKET REVENUE, BY GEOGRAPHY,2012 – 2017 ($MILLION)
TABLE 9 INSILICO IN CLINICAL TRIAL, MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
TABLE 10 NORTH AMERICA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS,2012 – 2017 ($MILLION)
TABLE 11 EUROPE: BIOSIMULATION MARKET REVENUE, BY SEGMENTS,2012 – 2017 ($MILLION)
TABLE 12 ASIA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS,2012 – 2017 ($MILLION)
TABLE 13 ROW: BIOSIMULATION MARKET REVENUE, BY SEGMENTS,2012 – 2017 ($MILLION)
TABLE 14 MERGERS & ACQUISITIONS, 2009 – 2012
TABLE 15 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS & JOINT VENTURES, 2009 – 2012
TABLE 16 NEW PRODUCT LAUNCHES, 2009 – 2012
 

LIST OF FIGURES

FIGURE 1 MARKET REVENUE FORECAST, 2012 – 2017
FIGURE 2 BUBBLE CHART: REGION WISE MARKET SHARE & GROWTH RATE
FIGURE 3 SEGMENTATION OF BIOSIMULATION MARKET
FIGURE 4 MARKET SHARE ANALYSIS OF MAJOR PLAYERS
FIGURE 5 APPLICATION OF BIOSIMULATION IN DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 6 MARKET SHARE BY SEGMENTS, 2011
FIGURE 7 MARKET SHARE BY APPLICATION, 2011
FIGURE 8 PROCEDURE OF PROTEIN STRUCTURE PREDICTION
FIGURE 9 INSILICO TARGET IDENTIFICATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 10 MARKET SHARE OF PROTEIN PREDICTING SOFTWARE & SERVERS, 2011
FIGURE 11 INSILICO TARGET VALIDATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 12 MARKET SHARE OF MOLECULAR MODELLING SOFTWARE & PROGRAMMES, 2011
FIGURE 13 INSILICO LEAD DISCOVERY MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 14 MARKET SHARE OF DE NOVO DESIGN SOFTWARE, 2011
FIGURE 15 INSILICO LEAD OPTIMIZATION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 16 MARKET SHARE OF QSAR MODELS, 2011
FIGURE 17 ANALYSIS OF MAIN REASONS FOR ATTRITION IN DRUG DEVELOPMENT
FIGURE 18 INSILICO ADME/TOX PREDICTION MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 19 ADME-TOX MARKET SHARE ANALYSIS, 2011
FIGURE 20 PK/PD MODEL REPRESENTATION
FIGURE 21 INSILICO PK/PD MODEL MARKET REVENUE, BY GEOGRAPHY,  2012 – 2017 ($MILLION)
FIGURE 22 PK/PD MARKET SHARE ANALYSIS, 2011
FIGURE 23 INSILICO IN CLINICAL TRIAL, MARKET REVENUE, BY GEOGRAPHY, 2012 – 2017 ($MILLION)
FIGURE 24 ACCEPTANCE LEVEL OF MODELLING & SIMULATIONS IN DRUG DISCOVERY & DEVELOPMENT PROCESS
FIGURE 25 MARKET ANALYSIS OF TECHNOLOGIES USED IN DRUG DISCOVERY & DEVELOPMENT
FIGURE 26 MODELLING AND SIMULATION IN PAEDIATRICS DRUG DEVELOPMENT
FIGURE 27 M&S IN PAEDIATRIC DRUG DEVELOPMENT
FIGURE 28 REGIONAL MARKER LIFE CYCLE ANALYSIS
FIGURE 29 BIOSIMULATION MARKET REVENUE GROWTH TREND, BY REGION, 2011& 2017
FIGURE 30 BIOSIMULATION MARKET GROWTH RATE, BY REGION, 2012 – 2017
FIGURE 31 BIOSIMULATION MARKET REVENUE, BY REGION, 2011 – 2017
FIGURE 32 NORTH AMERICA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 33 EUROPE: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 34 ASIA: BIOSIMULATION MARKET REVENUE, BY SEGMENTS, 2012 – 2017 ($MILLION)
FIGURE 35 ROW: BIOSIMULATION MARKET REVENUE, BY SEGMENTS,2012 – 2017 ($MILLION)
FIGURE 36 KEY GROWTH STRATEGIES, 2009 – 2012
FIGURE 37 PORTER’S FIVE FORCE ANALYSIS

The global pharmaceutical market in 2011 was valued at US$880 billion with an annual growth rate of 4%-6%; it is expected to grow at 4%-7% through 2013. Pharmaceutical companies nearly spend 15%-17% of their revenues in R&D for development and discovery of new drugs. As in traditional research practices it takes about 11-14 years for a pharmaceutical company in developing a new drug. It is estimated that the cost of new drug from its initial research stage to market entry is around US$800 million to US$1.5 Billion for over a period of 11-14 years.

Although R&D spending of pharmaceutical companies grew by 147%, there is only a 38% increase in the overall new drug applications (NDAs) submitted to FDA, and for innovative new molecular entities (NMEs) is has increased by only 7%. The ever increasing cost of developing drugs and decrease in productivity of R&D is forcing pharmaceutical companies to look for other alternative tools and practices that would not only shorten the R&D time cycle but also reduce the cost involved in the drug discovery process. One such tool is the biosimulation which promises to reduce the cost of drug discovery by predictive modelling and simulation.

Biosimulation means simulation of biological process and systems by computers; it is an integral part of systems biology. Biosimulation in drug discovery and development is the use of biosimulation (modelling and simulation) in drug discovery and development process which may also be referred as Computer Aided Drug Design (CADD) where computer models and simulations are used in various stages of drug discovery and development process.

Global biosimulation market is expected to reach 1.2 billion US$ by 2017 with the annual CAGR of 18.50%, and accounts for nearly 20% of the global bioinformatics market for R&D in drug discovery and development. Biosimulation is expected to account for 5% of the total US$ 68 billion drug discovery market in 7 to 10 years.

Biosimulation Market Share, By Geography

Biosimulation Market

Source: Secondary source, Expert interview, Markets and Markets Analysis

In 2011, the global biosimulation market was valued at $432 million. North America is the major market for the biosimulation and has been driving the global market significantly. Growth in North America is majorly driven by pharmaceutical companies in search for new drugs, as many of the companies’ patented drugs are coming off the shelf. Search for new drugs and cost reduction in R&D has been driving the growth of biosimulation. Europe is the second major market for biosimulation products majorly driven by government regulatory bodies which is promoting the use of biosimulation in drug discovery and development process. Asian market is an emerging market with increase in the growth of drug manufacturers and CRO’s in the region as a result of which the biosimulation market is expected to grow considerably over the next few years.

Biosimulation is a highly competitive market with many companies trying to capture market share with their niche capabilities. This market is dominated by few players and rest of the market is highly fragmented. Accelrys, inc. dominates the market followed by Certara, Schrodinger, Simulation plus, ACD/Labs, Insilico BioTechnology and LeadScope offering a range of solutions in the drug discovery and development process. With many firms operating in niche areas like CNS modelling and simulation platform, Rhenovia Pharma SAS leads the market followed by Insilico Biosciences.

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports